Day: November 29, 2022

Operating Income and Net Income Up Year-on-Year

Taipei, Taiwan, Nov. 29, 2022 (GLOBE NEWSWIRE) — Alchip Technologies set a fiscal year 2022 record with Q3 revenue reaching $117.5 million, reflecting a year-on-year increase of 28 percent over Q3 2021 revenue of $94.1 million, and a quarter-on-quarter increase of 16.2 percent over Q2 2022 revenue of $101.1 million.

Operating income for Q3 2022 is $18.6 million, representing a 21.9 percent year-on-year increase over Q3 2021 results of $14.4 million, but a decline of 3.6 percent from Q2 2022 operating income of $19.3 million.

Net income for Q3 2022 is $14.5 million, equating to a year-over-year increase of 12.6 percent over Q3 2021 net income of $12.9 million, and a slight 0.5 percent increase over Q2 2022 net income of $14.49 million.

Advanced technology, production and designs for 7nm and smaller line-width, accounted for 69 percent of Q3 2022 revenue and 66 percent of revenue for fiscal 2022 to date.  High-performance computing applications drove 78 percent of Q3 2022 revenue and 78 percent of revenue for fiscal year to date.

For the second consecutive quarter, North America, accounted for the largest share of Q3 2022 revenue at 39 percent, followed by Asia Pacific at 38 percent.  For fiscal year 2022, North America markets contributed 36% of revenue, after accounting for only 14 percent for all of 2021.

Management reports that Q3 revenue came mildly lower than expected because production revenue still suffered from tight ABF substrate supply constraints.

“On the other hand, design demand remained robust as most of the projected milestones came in on schedule, but profit margin was down due to a higher percentage of production revenue and other one-time expenses,” explained Alchip President and CEO, Johnny Shen.

Alchip is traded on the Taiwan stock exchange.  The company is extremely well respected in North America, Japan, Israel, Taiwan, and China for its high-performance ASIC design methodology, flexible business model, best-in-class IP portfolio and advanced packaging technology expertise.

For a more information on Alchip, go to www.alchip.com

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global provider of silicon and design and production services for system companies developing complex and high-volume ASICs and SoCs.  The company provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced, including 7nm, 6nm, 5nm and 4nm processes. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D package services, CoWoS/chiplet design and manufacturing experience. Customers include global leaders in AI, HPC/supercomputer, mobile phones, entertainment device, networking equipment and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661), is a TSMC-certified Value Chain Aggregator and is a founding member of the new TSMC 3DFabric Alliance®.

Attachment

• Alchip Q3’22 Revenue Breakdown by Process Node

Charles Byers
Alchip Technologies
+ (408)-310-9244
chuck_byers@alchip.com

GlobeNewswire Distribution ID 8703971

Solution Offers Public Cloud-like Scalability and Ease of Management in Customer Data Centers

SAN MATEO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — Cloudian^® today announced the launch of its HyperStore^® on-prem data lake storage in partnership with Snowflake, the Data Cloud company. Cloudian and Snowflake customers will now have access to data stored on HyperStore that is deployed on-premises in either a private cloud or hybrid cloud configuration. Designed from its inception to be fully S3 compatible, HyperStore provides the scalability and ease-of-management of a public cloud within an organization’s data center, offering enhanced performance, full control over security, data sovereignty, and reduced cost.

The combination of Cloudian and Snowflake addresses increasing interest from customers in running analytics applications on data in-place rather than having to move that data to a public cloud, which can be costly and time consuming. In addition to providing private cloud storage, HyperStore can also be deployed as part of a hybrid cloud strategy, with data being replicated or tiered to public cloud service providers.

Reflecting Cloudian’s leadership in object storage, it is the only vendor named a Gartner Peer Insights Customers’ Choice for Distributed File Systems and Object Storage¹ for three consecutive years². Key HyperStore benefits include:

• Modular, limitless scalability – Start with three low-cost nodes and expand simply by adding devices to the cluster without disrupting analytics workloads.
• Data resiliency – Get up to 14 nines of resiliency with administrator-defined data replication or erasure coding.
• Ransomware protection – Through S3 Object Lock, prevent malware from encrypting and/or deleting data — enabling quick, easy recovery without paying ransom — and meet governance and legal hold demands.
• Military-grade security – Further secure data with features such as secure shell, integrated firewall, RBAC/IAM access controls, AES-256 server-side encryption for data at rest and SSL for data in transit, as well as certification with the most stringent government security requirements.
• Multi-tenancy – Allow multiple users to store and analyze data within a single, shared data lakehouse — without compromising security — while also employing multi-tenant billing, metering and quality of service (QoS) controls.

“We look forward to seeing our joint customers unlock more value from their data through our partnership with Cloudian,” said Tarik Dwiek, Head of Technology Alliances at Snowflake. “Together, we work to enable our customers to take advantage of our joint solutions in order to move forward with mobilizing their data.”

“Analytics applications are providing new opportunities for organizations to leverage their digital assets, including on-premises data, to achieve their goals,” said Larry Meese, vice president of products and solutions, Cloudian. “We look forward to working with Snowflake to help customers capitalize on these opportunities by providing a robust, modern storage foundation.”

To learn more about the Cloudian-Snowflake solution, visit cloudian.com/snowflake/.

Gartner^® and Peer Insights are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Cloudian
Cloudian is the leader in data management software for the hybrid cloud. With military-grade security, limitless scalability and seamless cloud integration, Cloudian’s S3-compatible object storage lets users optimize data access, meet data sovereignty requirements and cut costs by consolidating information to a single, cloud-like platform. Cloudian’s geo-distributed architecture manages and protects object and file data at the edge, core, and in the cloud, for both conventional and modern applications. More at cloudian.com.

Media Contact
Jon Toor
mediainquiries@cloudian.com

¹ Gartner defines distributed file systems and object storage as software and hardware solutions that are based on “shared nothing architecture” and that support object and/or scale-out file technology to address requirements for unstructured data growth.
² Gartner, Gartner Peer Insights ‘Voice of the Customer’: Distributed File Systems and Object Storage, Peer Contributors, February. 6, 2020. Gartner, Gartner Peer Insights ‘Voice of the Customer’: Distributed File Systems and Object Storage, Peer Contributors, March 11, 2021. Gartner, Gartner Peer Insights ‘Voice of the Customer’: Distributed File Systems and Object Storage, Peer Contributors, April 22, 2022.

GlobeNewswire Distribution ID 8702781

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

• Deal validates Jeito’s unique investment model of selecting high–quality assets developed by world-leading teams in therapeutic areas with high unmet need

Paris, France, November 29^th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (“Neogene Therapeutics” or “Neogene”) to AstraZeneca a global, science-led biopharmaceutical company. Neogene is a global clinical-stage company pioneering the discovery, development, and manufacturing of next-generation T cell receptor therapies (TCR-Ts). Jeito co-led Neogene’s $110 million Series A financing marking the first investment since the launch of the fund.

Under the terms of the transaction, AstraZeneca will acquire all outstanding shares of Neogene for a total consideration of up to $320 million, on a cash and debt free basis. This will include an initial payment of $200 million on deal closing, and a further up to $120 million in both contingent, milestones-based and non-contingent considerations.

Since Jeito’s investment, Neogene has become a clinical stage company, and expanded both its pipeline of next-generation TCR-Ts and its manufacturing capabilities.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented: “This exit, Jeito’s first, represents a strong validation of our strategy of sourcing high-quality innovation in biopharma and supporting strong leadership teams as they identify the fastest route to bring much needed therapies to patients. This deal also illustrates the growing pharma demand for breakthrough innovation and by working with AstraZeneca, a global leader in oncology, we have every confidence that Neogene will be able to transform therapeutic options for people with hard-to-treat cancers. My congratulations go to everyone at Neogene on this fantastic achievement.”

Rachel Mears, Partner at Jeito, and Board Member of Neogene Therapeutics, added: “Over the course of our partnership, Neogene has successfully grown into a world-class cell therapy company, making key senior hires, expanding its pipeline of innovative TCR assets, and entering the clinic for the first time. Jeito has supported Neogene through key steps and the acquisition by AstraZeneca is a true demonstration that our approach combining deep scientific and industry expertise can create value for companies and in time, for patients as well.”

TCR-Ts are emerging as a promising therapeutic modality in cancer treatment. Most current cell therapy approaches in oncology focus on modifying the immune system’s T-cells to recognize proteins expressed on the surface of cancer cells. In contrast, TCR-Ts can recognize intracellular targets, including cancer-specific mutations, thereby potentially unlocking targets previously inaccessible using cell therapies.

Neogene was founded by Carsten Linnemann, PhD, Chief Executive Officer of Neogene, and Ton Schumacher, PhD, Principal Investigator at the Netherlands Cancer Institute, Oncode Institute in partnership with Two River, and cell therapy industry veteran Arie Belldegrun, MD, founder of Kite Pharma, Inc. and Co-Founder and Executive Chairman of Allogene Therapeutics, Inc. With Jeito’s support, Neogene expanded its senior leadership team in key business functions including manufacturing, operations, and clinical development.

Carsten Linnemann, PhD, Chief Executive Officer, Neogene, said: “We are excited to work together with AstraZeneca towards our shared mission of transforming the treatment options for patients with solid tumours using next-generation T-cell receptor therapies. Our expertise, clinical portfolio and platform technologies in this area combined with AstraZeneca’s leadership in oncology and global footprint mean we are well-positioned to translate pioneering science into novel treatments for hard-to-treat cancers. Our thanks go to Jeito Capital and all of our investors for their guidance and support.”

AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T cells, to more effectively fight cancer. Their research teams are exploring new ways to target and arm CAR-Ts to increase their effectiveness in solid tumors and working to engineer off-the-shelf patient-ready therapies already developed from the cells of healthy donors.

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About Neogene Therapeutics
Neogene Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and manufacturing next-generation, transformative TCR therapies targeting neoantigens in solid cancers. Neogene is advancing a pipeline of fully individualized TCR therapies as well as TCR therapies targeting shared neoantigens, including mutated KRAS (mKRAS) and mutated TP53 (mTP53).

Neogene was founded by Carsten Linnemann, PhD, Chief Executive Officer of Neogene, and Ton Schumacher, PhD, Principal Investigator at the Netherlands Cancer Institute, Oncode Institute in partnership with Two River, and cell therapy industry veteran Arie Belldegrun, MD, founder of Kite Pharma, Inc. and Co-Founder and Executive Chairman of Allogene Therapeutics, Inc. as well as key investments from Vida Ventures, TPG, EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners and Pontifax.

Neogene has EU headquarters in Amsterdam and U.S. headquarters in Santa Monica. Its team has deep gene and cell therapy expertise and a shared mission to bring next-generation transformative TCR therapies to patients with solid cancers worldwide. Please visit www.neogene.com and follow Neogene on LinkedIn.

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, EA
assia@jeito.life
Tel : +33 6 76 49 37 94

Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Marion Bougeard
marion@achto-conseil.fr
Tel : +33 6 76 73 57 31

GlobeNewswire Distribution ID 100076939

AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE

NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) — Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 – January 1, 2023.

Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. ‘Eyes in the Sky’ flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on December 4. Eyes on Iran aims to amplify the mission of Woman, Life, Freedom, a campaign demanding that the Islamic Republic of Iran is removed from the Commission on the Status of Women.

The New York installation was unveiled at an event featuring former U.S. Secretary of State Hillary Rodham Clinton, Human Rights Lawyer and Director of the Strategic Litigation Project at the Atlantic Council Gissou Nia, artists Sheida Soleimani and Shirin Neshat, actor and singer Sepideh Moafi and more at FDR Four Freedoms State Park with a performance by Grammy award-winner Jon Batiste. 

“We are calling on the world to take more action, starting at the United Nations. We must remove Iran from the U.N.’s Commission on the Status of Women. The fact that Iran is a member is a bitter irony,”  said Clinton. “What we are seeing is a revolution led by young women who are just not willing to live with the loss of freedom being imposed upon them.”

November 28 is significant because it is the anniversary of the 1943 Tehran Conference where Allied leaders, Franklin D. Roosevelt, Winston Churchill and Joseph Stalin met in Tehran to coordinate the Allied military strategy and also stated a shared desire for the maintenance of the independence, sovereignty, and territorial integrity of Iran. Today, Woman, Life, Freedom shares the call for human rights for the people of Iran.

“The world’s eyes have been focused on the courage of Iranian citizens in their quest for freedom, in the face of increasingly grave danger,” said human rights activist Nazanin Afshin-Jam Mackay. “The Islamic Republic has censored them and attempted to blind the world to the potential of this movement. ‘Eyes on Iran’ is our response to their call for a free Iran.”

“When we say that we must keep our ‘Eyes on Iran,’ we mean that what is happening deserves not only our attention but our vision. In solidarity with the courageous Iranians who are risking their lives to express their human rights, many artists throughout the diaspora and beyond are bringing our vision to bear to ensure international audiences and institutions remain aware of what is happening in Iran, in their eyes and in their hearts, and feel moved to respond,” says artist Shirin Neshat.

An interactive installation by artist JR will take place on December 4 at FDR Four Freedoms State Park. Eyes on Iran aims to amplify the mission of Woman, Life, Freedom, a campaign demanding that the Islamic Republic of Iran is removed from the Commission on the Status of Women. Additional artists featured online including Emily Elise, Mahdis Nikou, Priscillia Kounkou Hoveydam, Ernesto Yerena, Hourdad, Golnar Adili, and Anonymous Artists.

In October, the campaign published a two-page ad in The New York Times with a petition signed by women leaders from more than 14 countries, including Clinton, demanding the U.N. Member States remove the Islamic Republic of Iran from the Commission on the Status of Women. Within days, Prime Minister Jacinda Ardern of New Zealand, Canadian Deputy Prime Minister Chrystia Freeland, and Foreign Affairs Minister Melanie Joly, along with nearly 100,000 others, signed the petition.

The Woman, Life, Freedom campaign is a partnership between artist collective For Freedoms, a coalition of Iranian women leaders and Vital Voices Global Partnership, a non-profit elevating women leaders.

Key Links:

Press Images

Woman Life Freedom Website 

Press Release: Open Letter Calling for the Immediate Expulsion of the Islamic Republic of Iran from the UN Commission on the Status of Women

About Our Partners:

For Freedoms is an artist collective that centers art and creativity as a catalyst for transformative connection and collective liberation.  By wielding the power of art, we aim to deepen and expand our capacity to interrogate what is and imagine what could be.  Together, we seek infinite expansion.
www.forfreedoms.com

Vital Voices Global Partnership celebrates 25 years of directly investing in more than 20,000 women leaders across 184 countries since 1997. Driven by the universal truth that women are the key to progress in their communities and nations cannot move forward without women in leadership positions, Vital Voices has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, prime ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs.
www.vitalvoices.org

Four Freedoms Park Conservancy (FFPC), founded in 2011, operates under a Friends Agreement with New York State Parks to produce and curate public programs at Franklin D. Roosevelt Four Freedoms State Park. The park, designed by American modernist architect Louis Kahn, is among the greatest architectural masterpieces in New York City. By leveraging this spectacular architecture and the unique location of the park, the Conservancy produces events, installations,public art, and partners with local organizations that, together, serve a singular purpose: igniting the conversation around the Four Freedoms and the legacy of President Franklin D. Roosevelt.
www.fdrfourfreedomspark.org

The New York State Office of Parks, Recreation and Historic Preservation oversees more than 250 parks, historic sites, recreational trails, golf courses, boat launches and more, which are visited by more than 78 million people annually. For more information on any of these recreation areas, visit www.parks.ny.gov, download the free NY State Parks Explorer mobile app or call 518.474.0456. Also, connect on Facebook, Instagram and Twitter.

Attachments

• Shirin Neshat poses with her artwork at Eyes on Iran Art Exhibit by Woman Life Freedom
• Sec. Hillary Clinton speaks during Iran Press Preview for Woman Life Freedom

Sarah Brown McLeod
DEPARTMENT PR
sarah@department-pr.com